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Introduction
The presence of peripheral blood film acanthocytes can help narrow
the differential diagnosis of a familial choreiform disorder. Acanthocyto-
sis is associated with chorea–acanthocytosis (ChAc), McLeod syndrome,
pantothenate kinase-associated neurodegeneration (PKAN), and
Huntington’s disease-like 2 (HDL-2).1 Huntington disease (HD) can present
at a similar age with a similar phenotype, but without acanthocytosis. We
report the cases of three adult siblings with genetically confirmed ChAc,
and discuss the unusual finding of a co-existing abnormal HD allele (CAG
repeat expansion in the range of reduced penetrance) in two of these siblings.
Case series
Three siblings developed progressive neurological syndromes begin-
ning in their third or fourth decade (Table 1). Psychiatric symptoms were
an early feature in all siblings, including anxiety and obsessive–com-
pulsive features. Over the years, all siblings developed dysarthria and
orofacial features, including self-injurious biting, feeding dystonia, and
orofacial chorea. Siblings 1 and 3 developed epilepsy (complex partial
seizures in sibling 1 and generalized seizures in sibling 3). Limb chorea,
and frontal and temporal cognitive deficits occurred further into the
disease process, and were present in the elder siblings (1 and 2) by the
time of assessment. Sibling 1 died suddenly during follow-up and autopsy
suggested cardiorespiratory collapse as the cause of death.
Family history
There are seven siblings in this Irish family, three of whom are
unaffected. The final sibling reportedly has some neurological
symptoms but has not been fully investigated. There is no other
family history of neurological disorder, and no known consanguinity.
Investigations
Laboratory and imaging studies screening for biochemical,
infective, or autoimmune causes were unremarkable in each case.
Sibling 1 (the eldest) presented first and genetic testing for HD
demonstrated that he carried a single normal allele and a HD allele
with 37 CAG repeats, in the reduced penetrance range (also
subsequently identified in sibling 2). Investigation for ChAc was
prompted a short time later after siblings 2 and 3 were also evalu-
ated, because of recognition of the prominent orofacial features,
symptom onset in the 20s or 30s, and presence of acanthocytes in
peripheral blood. Genetic analysis of the VPS13A (ChAc) gene
(NM_033305.2) demonstrated that the three affected siblings are
compound heterozygotes, with one copy of the Arg3143fs*5 (c.9427_
9428delAG in exon 72) mutation that was previously reported in a
homozygous state in another (unrelated) Irish family from the same
region,2 and one copy of the novel Pro322Alafs*19 (c.962dupT in
exon 12) mutation. Both mutations cause a frameshift resulting in
a truncated protein. Genetic analysis of the unaffected mother and
one unaffected brother showed they each carry a single mutation
(Pro322Alafs*19). We assume that the Arg3143fs*5 mutation was
inherited from the siblings’ father, who had no history of neuro-
logical or psychiatric symptoms and died in his 40s of non-
neurological disease. Sibling 3 underwent HD testing at a later date
and was found to have 2 normal alleles.
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Post-mortem neuropathological findings in sibling 1
Findings in the brain were interpreted as consistent with ChAc.
There was prominent loss of neurons and gliosis in the caudate and to
a lesser extent the putamen and pallidum, with some early similar
changes within the substantia nigra. Furthermore, there was evidence
of chronic cerebrovascular disease with vascular lipohyalinosis, and
there were acute established changes of preterminal hypoxia-ischemia.
The spinal cord and sural nerve were normal. In the deltoid and
quadriceps muscles there were myopathic features with some fiber size
variability, increased number of fibers containing internal nuclei, type
I fiber predominance with grouping, and small type II fibers.
Discussion
ChAc is a rare autosomal recessive disorder caused by mutations of
the VPS13A gene on chromosome 9, which encodes the chorein protein.
The function of this protein is not well understood, but it is thought
to be involved in architecture of the cytoskeleton and cell survival.3
Cytoskeletal abnormalities may explain the unusual erythrocyte mor-
phology seen in this condition, but the degree of acanthocytosis is
variable and does not seem to correlate with clinical severity.4,5 Further-
more, while routine laboratory techniques actually demonstrate limited
sensitivity in detecting acanthocytosis, the use of isotonically diluted
blood and unfixed wet blood preparation improves sensitivity and
specificity.6 In addition, muscle creatine kinase is another useful blood
marker that is almost ubiquitously elevated in affected individuals.7
Symptoms of ChAc typically begin in the third decade (or less
frequently in the fourth decade) with dysphagia, dysarthria, chorea,
and unsteady or ‘‘rubber man’’’ gait.7 Involuntary movements of the
orofacial region, with feeding dystonia and self-mutilation from teeth
grinding and lip biting are characteristic of the disorder. Involuntary
vocalizations are frequent. Psychiatric symptoms, cognitive impair-
ment, epilepsy, and neuropathy are recognized non-motor symptoms.7
The phenotype of our patients is strongly suggestive of ChAc, with
orofacial dystonia, self-injurious behavior, and epilepsy early in the
Table 1. Clinical Characteristics of Affected Siblings
Sibling 1 Sibling 2 Sibling 3
Age at assessment 44 42 36
Gender Male Female Female
Age at symptom onset 36 38 28
First symptoms Psychiatric Psychiatric Epilepsy
Psychiatric symptoms 3 3 3
Dysphagia 3 3 7
Dysarthria 3 3 3
Self-injurious biting 7 3 3
Vocal tics 7 3 3
Orofacial chorea/dystonia 3 3 7
Truncal and limb chorea 3 3 7
‘‘Rubber man’’ gait 3 7 7
Cognitive deficits 3 3 7
Signs of peripheral neuropathy 3 3 7
Epilepsy 3 7 3
Peripheral blood acanthocytes 3 3 N/A
Creatine phosphokinase (U/L) (normal 40–180) 193 375 433
VPS13A gene mutation Compound heterozygote Compound heterozygote Compound heterozygote
Huntington disease allele Abnormal allele: 37 CAG Abnormal allele: 37 CAG Normal allele
Abbreviations: 3, Present; 7, Absent; N/A, Not available.
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disease. Their clinical features are certainly within the range of severity
and age of onset as that described in typical ChAc cases. However, the
co-existing VPS13A and HTT gene abnormalities were an interesting
finding in siblings 1 and 2. We propose that our patients have clear
clinical manifestations of ChAc and the finding of an abnormal HD
allele in the reduced penetrance range could simply be an incidental
finding. Indeed, post-mortem neuropathological findings in the eldest
sibling were consistent with the clinical diagnosis of ChAc, demon-
strating marked gliosis and extensive neuronal loss in the striatum (less
gliosis would be expected in HD, and neuronal loss should only be
extensive in advanced HD).8 Further support for the hypothesis that
the abnormal HD allele is an incidental finding includes evidence that
the incidence of the HD allele in the general population is almost
certainly higher than previously suspected. A recent large study repor-
ted 18 of 7,315 individuals from Western populations had >36 CAG
repeats (15 of these were in the reduced penetrance range of 36–
39 CAG repeats), suggesting an incidence of HD gene abnormalities
of approximately one in 400 in the general population.9 While
penetrance rates of up to 65% have been reported with 36–39 CAG
repeats in a cohort attending for diagnostic/predictive testing for HD
(i.e., in those with a known family history),10 the penetrance rate with
36–39 CAG repeats among the general population is closer to 0.2%
(although under-ascertainment of clinical cases or capturing indivi-
duals at a pre-symptomatic age is possible in a cross-sectional popu-
lation study such as this).9 On the other hand, an alternative hypothesis
that should be considered is that, should the remaining affected sibling
with the CAG repeat expansion live long enough, she could experience
a ‘‘double-hit’’ from both genetic abnormalities, resulting in compound
neurodegenerative changes in affected regions. CAG repeat length
demonstrates an inverse correlation with age of onset;11 therefore, HD
alleles in the reduced penetrance range that become symptomatic
typically cause late-onset disease, sometimes with no family history
of the disorder.12 However, accurately determining age of onset is
challenging in HD,13 and we expect that the co-existence of another
choreiform disorder seen in our patients could make this almost
impossible to define. This being said, we will certainly monitor the
surviving siblings closely for evolution of phenotype over time, and
it will be particularly useful to compare the clinical course of the sibling
with the abnormal HD allele to the sibling without this abnormality.
A final important issue raised in this family is the implications of
detection of the HD allele in the reduced penetrance range for
subsequent generations. Regardless of whether an individual carrying
this abnormal allele becomes symptomatic in their lifetime, there is a
possibility of anticipation with expansion of CAG repeats between
parent and offspring, a phenomenon that occurs far more commonly
with paternal transmission of the gene.14 The deceased male sibling 1
has one son who has received genetic counseling and will be followed
by clinical genetics over the long term.
Conclusion
We report an Irish kindred with classic presenting features of ChAc,
who are compound heterozygotes for this rare neurodegenerative
disorder, but also carry a reduced penetrance range expansion of the
HTT gene. This case series emphasizes the importance of a detailed
family history and clinical examination in the assessment of chorea, and
the diagnostic utility of identifying acanthocytes on a peripheral blood
film. With recent studies elucidating potential pathophysiologic pathways
in ChAc,15–17 potential therapeutic targets may be identified in future.
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